03 November 2014 | News | By BioSpectrum Bureau
TWi receives FDA approval for generic Alzheimer's drug
according to IMS health Aricept's US sales were approximately $78 million for the 12 months ended June 2014
Singapore: FDA has given a nod to TWi pharmaceuticals ANDA for Donepezil Hydrochloride Tablets USP, 23 mg, the generic equivalent to Eisai's Aricept 23mg. The drug is used to treat Alzheimer's disease patients.
The Taiwan-based company said in its press release that the product will be launched at the earliest in the US via its fully owned subsidiary, TWi Pharmaceuticals USA. The drug increases the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase.